Advertisement
Singapore markets closed
  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • Dow

    37,753.31
    -45.66 (-0.12%)
     
  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     
  • Bitcoin USD

    61,879.28
    -628.35 (-1.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,861.31
    +13.32 (+0.17%)
     
  • Gold

    2,398.80
    +10.40 (+0.44%)
     
  • Crude Oil

    82.30
    -0.39 (-0.47%)
     
  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     
  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     
  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     
  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     
  • Jakarta Composite Index

    7,166.81
    +35.97 (+0.50%)
     
  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Huntsman (HUN) Wraps Up Gabriel Performance Acquisition

Huntsman Corporation HUN recently announced the completion of the purchase of Gabriel Performance Products from funds owned by Audax Private Equity. Gabriel is a North America-based specialty chemical manufacturer of specialty additives and epoxy curing agents for the coatings, adhesives, sealants as well as composite end-markets.

It was an all-cash transaction wherein Huntsman paid $250 million that was funded from available liquidity, subject to customary closing adjustments.

Gabriel has three manufacturing facilities in Ashtabula, OH, Harrison City, PA and Rock Hill, SC. The company’s revenues for 2019 were roughly $106 million. Based on 2019, the acquisition price reflects an adjusted EBITDA multiple of around 11 times or roughly eight times pro forma for synergies.

The acquisition of Gabriel is expected to complement Huntsman’s recent acquisition of CVC Thermoset Specialties. It is also expected to provide significant commercial synergies as the company expands and globalizes its specialty products portfolio.

ADVERTISEMENT

Shares of Huntsman have increased 23.4% in the past year compared with 21.8% rise of its industry.

The company expects fourth-quarter adjusted EBITDA for its Polyurethanes and Performance Products segments to be better than third-quarter levels.

In its Performance Products segment, the fourth-quarter adjusted EBITDA is expected to be higher than third-quarter figures by around 15%. In the Advanced material segment, it is projected to be in-line with third-quarter levels. In the Textile Effects segment, the same is projected to be roughly in line with fourth-quarter 2019 levels.

Huntsman is on track with integrating two downstream acquisitions completed last year and generating more than $100 million of targeted annualized savings from its cost-optimization initiative by the end of this year. The company is also focused on growth of its differentiated businesses and enhancing shareholders’ value.

Huntsman Corporation Price and Consensus

 

Huntsman Corporation Price and Consensus
Huntsman Corporation Price and Consensus

Huntsman Corporation price-consensus-chart | Huntsman Corporation Quote

 

Zacks Rank & Other Key Picks

Huntsman currently sports a Zacks Rank #1 (Strong Buy).

Some other top-ranked stocks in the basic materials space are Fortescue Metals Group Limited FSUGY, BHP Group BHP and Impala Platinum Holdings Limited IMPUY.

Fortescue has a projected earnings growth rate of 75.5% for the current fiscal. The company’s shares have surged around 132.6% in a year. It currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

BHP has an expected earnings growth rate of 59.5% for the current fiscal. The company’s shares have gained around 28.5% in the past year. It currently flaunts a Zacks Rank #1.

Impala has an expected earnings growth rate of 189.4% for the current fiscal. The company’s shares have rallied around 43.7% in the past year. It currently sports a Zacks Rank #1.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BHP Group Limited (BHP) : Free Stock Analysis Report
 
Impala Platinum Holdings Ltd. (IMPUY) : Free Stock Analysis Report
 
Huntsman Corporation (HUN) : Free Stock Analysis Report
 
Fortescue Metals Group Ltd. (FSUGY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.